You are currently viewing a new version of our website. To view the old version click .

Recent Advances in Anticancer Strategies, 2nd Edition

Topic Information

Dear Colleagues,

The topic "Recent Advances in Anticancer Strategies, 2nd Edition" aims to provide an overview of the latest developments in the field of cancer treatment. Cancer remains one of the leading causes of death worldwide, and researchers have been working to develop more effective and targeted treatments to improve outcomes for patients. The existing cancer therapies suffer from severe side-effects and drug resistance, leading to an increase in cancer incidence and mortality worldwide. Hence, there is a pressing need to develop and discover novel therapeutic strategies that can offer more effective and less-toxic treatment options for cancer patients. Novel anticancer approaches are being developed which can selectively identify and eliminate cancerous cells while minimizing harm to healthy tissues, unlike traditional therapies.

For this topic, we welcome original articles and comprehensive reviews that showcase the latest advances in novel anticancer strategies with reduced toxicity and improved therapeutic indices. These articles can suggest potential prospects for optimizing cancer therapies with significant clinical value in the near future. We encourage submissions that focus on the development and validation of various anticancer approaches, including ligand-/receptor-based targeting, controlled drug delivery, gene therapy, gene delivery, immunotherapy, targeted anticancer prodrugs and conjugates (such as photoactivatable caged prodrugs, ADEPT, ADAPT, and ADCs), magnetic- and ultrasound-mediated drug targeting, and cancer stem cell therapy, as well as strategies that explore the targeting of signaling cascades and the tumor microenvironment.

Overall, this topic aims at providing recent advances in anticancer strategies, highlighting the potential impact of these new approaches on cancer treatment and patient outcomes. We eagerly anticipate your valuable contribution to this exciting topic.

Dr. Hassan Bousbaa
Dr. Zhiwei Hu
Topic Editors

Keywords

  • anticancer strategies
  • cancer treatment
  • chemotherapy
  • radiation therapy
  • immunotherapy
  • targeted therapy
  • gene therapy
  • stem cell therapy
  • precision medicine
  • combination therapy
  • biomarkers
  • drug delivery
  • nanoparticles
  • CAR-T cell therapy
  • checkpoint inhibitors
  • epigenetic therapy
  • oncolytic viruses
  • artificial intelligence in cancer treatment
Graphical abstract

Participating Journals

Cancers
Open Access
33,906 Articles
Launched in 2009
4.4Impact Factor
8.8CiteScore
20 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking
International Journal of Molecular Sciences
Open Access
104,610 Articles
Launched in 2000
4.9Impact Factor
9.0CiteScore
20 DaysMedian Time to First Decision
Q1Highest JCR Category Ranking
Pharmaceuticals
Open Access
9,618 Articles
Launched in 2004
4.8Impact Factor
7.7CiteScore
14 DaysMedian Time to First Decision
Q1Highest JCR Category Ranking
Pharmaceutics
Open Access
13,449 Articles
Launched in 2009
5.5Impact Factor
10.0CiteScore
15 DaysMedian Time to First Decision
Q1Highest JCR Category Ranking
Scientia Pharmaceutica
Open Access
1,564 Articles
Launched in 1930
2.5Impact Factor
4.6CiteScore
38 DaysMedian Time to First Decision
Q3Highest JCR Category Ranking
Current Oncology
Open Access
5,046 Articles
Launched in 1994
3.4Impact Factor
4.9CiteScore
21 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking
Molecules
Open Access
61,764 Articles
Launched in 1996
4.6Impact Factor
8.6CiteScore
16 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking

Published Papers